CD274 and myocarditis: In a phase 1b trial of 55 patients treated with avelumab (anti-PD-L1 monoclonal antibody) plus axitinib (a vascular endothelial growth factor [VEGF] inhibitor), only one (1.8%) case developed lethal myocarditis (Choueiri et al., 2018).